Remove 2003 Remove Licensing Remove Marketing Remove Virus
article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69
article thumbnail

Blocked Transmission

Codon

It was March 2003, and an unfortunate 33-year-old, known only as patient YY, was suffering from intense diarrhea. Patient YY’s neighbors quickly started to become infected, passing on the virus in turn. Tom Ough writes about how UVC light, metals, and surface coatings can help fend off pathogens for Issue 01. Always free.

Virus 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

U.S. FDA ACCEPTS FOR PRIORITY REVIEW

The Pharma Data

Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. About TicoVac (TBE vaccine, whole virus inactivated).

FDA 52
article thumbnail

How the Fifty States View Electronic Data as a “Product”

Drug & Device Law

2003), an Internal Revenue Service regulation, excluded liability for “product” refund, repair or replacement. 23, 37 (2003) (“the phrase refers to the producer of the tangible goods that are offered for sale, and not to the author of any idea, concept, or communication embodied in those goods”). 2003), review denied (Cal.